Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

Cara Therapeutics stock opened at $5.15 on Friday. The firm has a market capitalization of $23.56 million, a P/E ratio of -0.25 and a beta of 0.50. The company has a 50-day simple moving average of $5.07 and a 200-day simple moving average of $4.24. Cara Therapeutics has a one year low of $2.71 and a one year high of $11.39.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CARA. XTX Topco Ltd bought a new position in shares of Cara Therapeutics in the third quarter worth $29,000. FMR LLC grew its position in Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 32,789 shares in the last quarter. Curi RMB Capital LLC bought a new position in Cara Therapeutics in the 4th quarter valued at about $277,000. Shay Capital LLC bought a new stake in shares of Cara Therapeutics during the 4th quarter worth about $524,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Cara Therapeutics during the 4th quarter worth about $953,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.